With an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.
Nitrogenases also can fix CO2
Latest NewsInvestigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis
Sphingotec secures Series C financing
Latest NewsGerman diagnostics specialist SphingoTec GmbH has closed a €5m Series C financing round led by Think.Health Ventures.
New antibiotic breaks resistance
Latest NewsA Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.
DiogenX strengthens its management team
AppointmentsThe biotech company DiogenX, based in Marseille (F), has appointed Hélène Sicard, PhD, as Chief Development Officer.
Roche inks US$2bn biobucks deal with Sangamo
Latest NewsAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Carbios SAS to expand PET recycling portfolio to the UK
Latest NewsFrench bioplastics recycling specialist Carbios SAS and British recycling and waste management company FCC Environment want to establish a PET biorecycling facility in the UK.
FDA approves cell therapy for solid tumours
Latest NewsThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
Experienced CEO appointed
AppointmentsLori A. Ball has been appointed as the new Chief Executive Officer of UK-based Astoriom. She will be responsible for driving the development of Astoriom’s sample management business in the US, UK and Europe.
Valneva licences LimmaTech’s Shigella vaccine
Latest NewsFrench-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.
BI Venture Funds invests in oncolytic bacteria
Latest NewsWith an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.